DB05637Investigational
CERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. It was under investigation in... It was under investigation in clinical trials for the treatment of Parkinson's Disease.
- Primary indication
- Investigated for use/treatment in parkinson's disease.Curator reviewed
- Also known as
- AAV2-Neurturin · adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]
- Code names
- CERE-120
Resolves to
Compound
What you can answer from here — as of April 02, 2025
Which companies are running trials of CERE-120, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account